I reiterated my ‘Strong Buy’ rating for Danaher (NYSE: DHR ) in my previous article published in April 2024, pointing out Danaher’s worst time has already passed. The company’s Q2 result on July 23 demonstrated furtherMore than 15 years of professional investment experience in global equities across all sectors. My investment style is fundamental, bottom-up, long-term, and quality growth-oriented. I am seeking companies specializing in niche markets, with strong growth potential, a solid management team, a ...

Dublin, Sept. 24, 2024 (GLOBE NEWSWIRE) -- The "Global Automated and Closed Cell Therapy Market 2024-2029" report has been added to ResearchAndMarkets.com's offering. In 2023, the global market for automated and closed cell therapy was valued at $1.5 billion. The market is forecast to grow at a CAGR of 23.9% to reach $5.3 billion at the end of 2029. The report highlights the current and future market potential of automated and closed cell therapy systems and a detailed analysis of the market drivers, restr ...

WASHINGTON, Sept. 19, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2024 on Tuesday, October 22, 2024 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations.The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheadin ...

BREA, Calif. and TEL AVIV, Israel, Sept. 17, 2024 /PRNewswire/ -- Beckman Coulter, a clinical diagnostics leader, and Scopio Labs, a medtech company that develops digital cell morphology workflow solutions, today jointly announced expansion of its long-term partnership to include a global distribution agreement of Scopio's Full-Field Bone Marrow Aspirate™ (FF-BMA) Application. Scopio's X100 / X100HT with FF-BMA Application are CE-Marked. Bone marrow aspirate analysis is a vital procedure providing essential ...

WASHINGTON, Sept. 10, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common stock, payable on October 25, 2024 to holders of record on September 27, 2024. ABOUT DANAHER Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of t ...

Danaher Corporation (DHR) has been benefiting from strength in its Diagnostics segment and accretive acquisitions. The company's measures to reward its shareholders are encouraging. Let's discuss the factors that should influence investors to retain this Zacks Rank #3 (Hold) company for the time being. Growth Catalysts of DHR Business Strength: Strength in Danaher's clinical diagnostics business, driven by growth in Leica Biosystems and Beckman Colter Diagnostics units, has been supporting the Diagnostics s ...

WASHINGTON, Sept. 4, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") confirmed its previously issued guidance for the third quarter and full year 2024 ahead of a previously scheduled analyst event.The Company provides forecasted sales only on a non-GAAP core revenue basis because of the difficulty in estimating the other components of GAAP revenue, such as currency translation, acquisitions and divested product lines.  For both the third quarter and full year 2024, the Company continues ...

WASHINGTON, Aug. 26, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) will host a live video webcast of its Diagnostics Investor and Analyst Meeting in Washington, D.C. on September 5, 2024 beginning at approximately 10:00 a.m. ET. The event will be hosted by Julie Sawyer Montgomery, Executive Vice President, Diagnostics. A link to the webcast and accompanying slide presentation will be available on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentatio ...

PM Images Introduction A blended P/E ratio of 36x. 0% EPS growth in 2024. I think it's fair to say that this does not look like a winning combination. Especially in light of what I wrote in a recent article titled "Buying Wonderful Businesses At Fair Prices - The Billionaire Way," it may be weird that I give you a stock with a lofty valuation and no expected growth in 2024. One of the "Buffett-style" checklist items was to make sure we buy companies trading at a discount. [...] do you fully understand the ...

It has been about a month since the last earnings report for Danaher (DHR) . Shares have added about 2% in that time frame, underperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Danaher due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Danaher Q2 Earnings Beat, Biotechnology Sales Dip Y/YD ...